Older patients (age 65 years or older) and patients not fit for intensive chemotherapy (based on predicted high early mortality) are now offered low-intensity strategies using combinations of cladribine and low-dose cytarabine alternating with decitabine or azacitidine together with venetoclax; decitabine (10-day induction, 5-day maintenance) combined with venetoclax, and other HMAs (e.g., oral decitabine) plus venetoclax-based combinations that also incorporate FLT3 inhibitors (if FLT3-mutated AML), IDH inhibitors (if IDH-mutated AML), or APR246 or magrolimab (if TP53-mutated AML). The gene discussed is FLT3; the disease is acute myeloid leukemia.